Supreme Court justices grappled with the standard to apply in determining whether a test that correlates a drug’s metabolites to proper dosage is patent-eligible during Dec. 7 oral arguments in Mayo Collaborative Services v. Prometheus Laboratories Inc.
The justices questioned Mayo’s contention that Prometheus’s patent simply covers a natural phenomenon. But they also asked whether the application...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?